Drug Discovery World

OCTOBER 23, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

Production 52

Production In-Vitro Reagent DNA 52

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? DDW’s Megan Thomas finds out. He says: “In recent years, the field has seen exponential growth, which has outpaced the rate at which new professionals enter.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

The Pharma Data

AUGUST 4, 2020

Accurate monitoring of Epstein-Barr virus DNA levels is critical, as they are associated with a range of life threatening-diseases including cancer in transplant patients. This is the first quantitative in vitro diagnostic test for Epstein-Barr virus (EBV) DNA in the United States.

DNA 52

DNA In-Vitro Medicine Reagent 52

Drug Discovery World

FEBRUARY 27, 2023

which removes the mandatory requirement for animal testing in the development of drugs for toxicity where enhanced performance is proven using in vitro alternatives. The company also debuted its Zephyr G3 NGS iQ workstation, an integrated benchtop system that enables the automated construction of up to 96 NGS libraries.

Drugs 52

Drugs Life Science Protein Scientist 52

The Pharma Data

SEPTEMBER 7, 2020

to obtain comparable results when measuring levels of BKV DNA. The test offers an alternative to lab-developed tests (LDTs) or Analyte Specific Reagent (ASR) combinations, potentially minimising variability and complexity in testing, reducing workload and alleviating risk for laboratories. IU/mL and an expanded linear range from 21.5

In-Vitro 52

In-Vitro Medicine Reagent DNA 52

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

Drug Discovery World

OCTOBER 14, 2022

Reducing assay volumes from about 200 µL to 1 µL ha s cut the quantities of reagents and consumables needed, while automation has replaced manual handling, so lowering running and personnel costs. . The rapid evolution of HTS to meet industry demand . Overcoming challenges in HTS using mass spectrometry .

Drugs 52

Drugs In-Vitro Development Production 52